Novartis Ag

Irm LLC

Novatis Ag

Vernalis Limited

Joseph Schoepfer

Pascal Furet

Paul William Manley

Andreas Marzinzik

Bahaa Salem

Wolfgang Jahnke

Robert Martin Grotzfeld

Xavier Francois Andre Pelle

Darryl Jones

Nathanael Schiander Gray

Yi Liu

Guido Bold

Vito Guagnano

Clive McCarthy

Carsten Spanka

Saliha Moussaoui

Stefan Stutz

Marc Lang

Giorgio Caravatti

Andrea Vaupel

Werner Breitenstein

Tetsuo Uno

Qiang Ding

Guobao Zhang

Bing Li

Keiichi Masuya

Ruo W Steensma

Philipp Holzer

Taebo Sim

Carlos Garcia-Echeverria

Stephanie Kay Dodd

Patricia Imbach

Niko Schmiedeberg

Carole Pissot Soldermann

Frédéric Zecri

Andreas Floersheimer

Vincent Bordas

Greg Chopiuk

Ross Strang

Jürgen Hans-Hermann Hinrichs

Markus Furegati

Henrik Möbitz

Fatma Limam

Michael Rugaard Jensen

Jacques Hamon

Jvan Brun

Sandro Nocito

Melanie Stang

Erich Alois Spieser

Simone Plattner

Darryl Brynley Jones

Thomas Radimerski

Cornelia Quadt

The present invention provides a compound, or a pharmaceutically acceptable salt thereof, of formula (I): wherein R, R, R, R, R, R, R, y, R, M, W, L, V, T, Y, J, K and A are as described herein, therapeutic uses of said compounds, uses of said compounds as research chemicals, a pharmaceutical composition and combinations comprising said compounds, and methods for manufacturing the compounds of the invention.

Bicyclic compounds and their uses

The present invention relates to compounds of formula (I): 

Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1

The present invention relates to compounds of formula I: 

Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1

The present invention relates to compounds of formula (I): in which Y, Y, R, R 2, R 3 and R 4 are defined in the Summary of the Invention; capable of inhibiting the tyrosine kinase enzymatic activity of the Abelson protein (ABL1), the Abelson-related protein (ABL2) and related chimeric proteins, in particular BCR-ABL1. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers. 

The present invention relates to compounds of formula I: in which Y, Y, Y, Y, Y, R, R, Rand Rare defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers. 

The present invention relates to compounds of formula (I): in which Y, Y, R, R 2, R 3 and R 4 are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers. 

The invention relates to compounds of formula (I) and salts thereof wherein the substituents are as defined in the specification, the application of a compound of formula (I) in a process for the treatment of the human or animal body, in particular with regard to C-Met tyrosine kinase mediated disease; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner; processes for the preparation of a compound of formula (I).

3-Methyl-imidazo[1,2-b]pyridazine derivatives

The invention relates to compounds of formula (I) wherein the substituents X, R, R, Rand Rhave the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.

Compounds and compositions as protein kinase inhibitors

3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives

The invention relates to naphthalene carboxylic acid and isoquinoline carboxylic acid amides, and related compounds of formula I and their uses as pharmaceuticals.

Organic compounds

The invention relates to thiazole and pyrazole derivatives of formula (I) wherein Q is S and X is C, or Q is CH and X is N; Ris unsubstituted or substituted phenyl; and Ris unsubstituted or substituted aryl or heteroaryl; or a salt of the said compounds, and to processes for the preparation thereof, to pharmaceutical compositions comprising such derivatives and to the use of such derivatives for the preparation of pharmaceutical compositions for the treatment especially of a proliferative disease, such as a tumour disease, in particular such diseases which respond to an inhibition of the Flt-3 kinase. 

Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, EGF-R, c-erbB2 kinase (HER-2), CHK2, FGFR3, p70S6K, PKC, PDGF-R, p38, TGF&#x3b2;, KDR, c-Kit, b-RAF, c-RAF, FLT1 and/or FLT4 kinases.

Methods and compositions as protein kinase inhibitors

Growing community of inventors

Riehen, Switzerland

Joseph Schoepfer